Prestige Biologics: Q3 Operating Loss of KRW 39.7bn, Debt Ratio Soars to 149%, Cash Depleted

Debt ratio 149% (previous year 100%), cash and cash equivalents plummeted to KRW 0.66bn, short-term borrowing of KRW 15bn arranged.
Operating loss KRW 39.7bn, net loss KRW 35.9bn, persistent deficit; sales KRW 12.3bn.
Financial liabilities total KRW 104.3bn (convertible bonds KRW 47.5bn, long-term borrowings KRW 37.6bn); KRW 90.5bn maturing within one year.
Lawsuit of KRW 7.6bn pending (defendant, construction payment claim by Shin Sung ENG).
R&D expenses KRW 17.7bn (144% of sales).
HD201 obtained European marketing authorization (positive); CDMO utilization rate 69.4% (previous year 31.3%).
Order backlog: USD 34.1mn, KRW 15.8bn.